We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

HospiMedica

Download Mobile App
Recent News Medica 2024 AI Critical Care Surgical Techniques Patient Care Health IT Point of Care Business Focus

Efforts to Contain SARS Showing Progress

By HospiMedica staff writers
Posted on 28 May 2003
Health measures designed to rein in the virus causing severe acute respiratory disease (SARS) are proving to be effective in many countries, according to scientists recently convened by the World Health Organization (WHO, Geneva, Switzerland) to review the latest data on the disease.

The consensus was that health measures that have contributed to this progress are the earliest possible detection and treatment of people suspected of having SARS, the immediate quarantining of all those who have had any contact with them, and early information and travel warnings to the public on areas with dangerous outbreaks of SARS.

The scientists found no evidence that insects or animals can spread the virus, and no evidence was found that infected individuals were able to spread the virus before becoming ill. Data have confirmed that the virus is mainly spread by droplets from the sneezes and coughs of infected people to those who have been in close contact with them. People with SARS appear to be most infectious during the second week of illness. However, all cases should be treated as highly infectious from the very first symptom in order to minimize the possibility of transmission to others.

In a related development, German researchers have found that an experimental drug tested as a common cold remedy might be modified to fight the SARS virus. The drug, known as AG-7088, is in clinical trials for treatment of rhinovirus, which causes colds. The compound itself could not be used to treat SARS but it could represent a good starting point for designing a SARS drug, reported the researchers, from the University of Luebeck (Germany).


Gold Member
12-Channel ECG
CM1200B
Gold Member
POC Blood Gas Analyzer
Stat Profile Prime Plus
New
Clinical Display
C14S
New
Cementless Partial Knee
Oxford

Latest Patient Care News

Portable Biosensor Platform to Reduce Hospital-Acquired Infections

First-Of-Its-Kind Portable Germicidal Light Technology Disinfects High-Touch Clinical Surfaces in Seconds

Surgical Capacity Optimization Solution Helps Hospitals Boost OR Utilization